Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Objective

This randomized phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy with atezolizumab may work better than combination chemotherapy alone in treating patients with colon cancer.

https://www.clinicaltrials.gov/ct2/show/NCT02912559

Contact Phone: 218-786-3308 | 1-844-681-7944

Email: cancertrials@essentiahealth.org

Locations: Essentia Health Cancer Centers

Disclosures:

None

For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.

Last Updated: 06/07/2018

Research Study Categories

  • Adult Studies

Specialty

  • Cancer
  • Gastrointestinal Cancer